Osteoporosis International

, Volume 21, Issue 4, pp 705–708

Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies

Case Report


Reports of femoral shaft fractures in patients on long-term bisphosphonates (BPs) have raised important concerns on the safety for this class of drugs. Patients with malignancies are potentially at a higher risk for this complication considering the dose and the duration of treatment with BPs. In this report we describe the case of 56-year-old woman with multiple myeloma who developed a non-traumatic left femoral shaft fracture after treatment with high dose BPs for 6 years, following a bone marrow transplant. Intramedullary rod fixation of the fractured femur resulted in “splitting” of the fractured bone followed by poor healing and nonunion of the fractured bone. This case illustrates a potential problem in the management of patients with femoral shaft fractures from prolonged BPs, most especially those who are on high doses for malignant conditions. However, considering the number of patients who benefit from BPs, this complication should not discourage clinicians from using these agents in patients where treatment is indicated.


Bisphosphonates Femoral fractures Malignancies 


  1. 1.
    Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301CrossRefPubMedGoogle Scholar
  2. 2.
    Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355(19):2048–2050CrossRefPubMedGoogle Scholar
  3. 3.
    Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93(8):2948–2952CrossRefPubMedGoogle Scholar
  4. 4.
    Odvina CV, Levy S, Rao S, Zerwekh JE, Sudhaker RD. Unusual mid-shaft fractures during long term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009, March 19Google Scholar
  5. 5.
    Kyle RA, Yee GC, Somerfield MR et al (2007) American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25(17):2464–2472CrossRefPubMedGoogle Scholar
  6. 6.
    Rosen LS, Gordon D, Kaminski M et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735–1744CrossRefPubMedGoogle Scholar
  7. 7.
    Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090CrossRefPubMedGoogle Scholar
  8. 8.
    Cook JR (2008) Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD). Abstract, 2008 ASCO Annual MeetingGoogle Scholar
  9. 9.
    Lenart BA, Neviaser AS, Lyman S et al. (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362Google Scholar
  10. 10.
    Schneider JP (2006) Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 61(1):31–33PubMedGoogle Scholar
  11. 11.
    Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358(12):1304–1306CrossRefPubMedGoogle Scholar
  12. 12.
    Kwek EB, Goh SK, Koh JS, Png MA, Howe TS (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39(2):224–231CrossRefPubMedGoogle Scholar
  13. 13.
    Goh SK, Yang KY, Koh JS et al (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89(3):349–353CrossRefPubMedGoogle Scholar
  14. 14.
    Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15(4):613–620CrossRefPubMedGoogle Scholar
  15. 15.
    Mashiba T, Turner CH, Hirano T et al (2001) Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29(3):271–278CrossRefPubMedGoogle Scholar
  16. 16.
    Bailey AJ, Paul RG, Knott L (1998) Mechanisms of maturation and ageing of collagen. Mech Ageing Dev 106(1–2):1–56CrossRefPubMedGoogle Scholar
  17. 17.
    Gundberg CM, Anderson M, Dickson I, Gallop PM (1986) "Glycated" osteocalcin in human and bovine bone. The effect of age. J Biol Chem 261(31):14557–14561PubMedGoogle Scholar
  18. 18.
    Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP (2001) Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28(2):195–201CrossRefPubMedGoogle Scholar
  19. 19.
    Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D (2009) Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 20(6):887–894CrossRefPubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2009

Authors and Affiliations

  1. 1.Division of Bone and Mineral DiseasesWashington University School of MedicineSt. LouisUSA
  2. 2.Division of EndocrinologyUniversità Campus Bio-MedicoRomeItaly

Personalised recommendations